Emergent BioSolutions, Inc.'s BARDA Biothrax contract extended
Emergent Product Development Gaithersburg, Inc., a wholly-owned subsidiary of Emergent BioSolutions, Inc., said that it plans to extend a contract made with the U.S. Biomedical Advanced Research and Development Authority and the U.S. Department of Health and Human Services, according to Benzinga.com.
The existing contract for the development of a recombinant protective antigen anthrax vaccine runs through September 18, 2012.
The modified contract will extend the base period of performance of the contract through January 20, 2013. In addition, the contract's milestone table and deliverables will be modified to incorporate the new base period of performance.
Emergent BioSolutions, Inc., is the producer of the only anthrax vaccine currently approved by the U.S. Food and Drug Administration. The vaccine, BioThrax, is indicated for the immunization of adults with a high risk of exposure to anthrax. It is manufactured from a non-virulent strain of the bacteria Bacillus anthracis.
BioThrax has been administered to approximately 2.7 million individuals. The U.S. government has articulated a need to stockpile 75 million doses of the vaccine and, towards that end, awarded Emergent BioSolutions, Inc., a contract to supply 44.75 million doses over the next five years, according to SeekingAlpha.com.